1. INTRODUCTION 
1.2. BACKGROUND INFORMATION ON COOP 
1.2.2. Pharmacokinetic Data 
1.2.3. In vitro studies of CDDP metabolizing enzymes I Drug interactions 
1.2.4. Clinical data 
1.3. BACKGROUND ON 5 FU 
1.3.1. Mechanism of action 
1.3.2. Pharmacokinetic data 
1.3.3.1. Safety 
1.3.3.2. Activity 
1.4.2. Rationale for the selection of the test arm TXT CDDP 5 FU for the phase Ill part 
1.4.2.2. Selection of the test arm for the phase Iff by the IDMC 
2. STUDY OBJECTIVE(S) 
3. OVERALL STUDY DESIGN 
3.1. DESCRIPTION AND RATIONALE OF THE DESIGN 
3.2. STUDY CENTERS 
3.3. REFERENCE COMMITTEES 
3.3.1. lndependant Data Monitoring Committee (IDMC) 
3.3.2. External Response Review Committee (ERRC) 
4. SELECTION OF STUDY POPULATION 
4.2. INCLUSION CRITERIA 
4.3. EXCLUSION CRITERIA 
4.4. REMOVAL OF PATIENTS FROM THERAPY OR ASSESSMENT 
5. PLAN OF THE STUDY 
5.1. STUDY PERIOD 
5.2. DETAILED PLAN 
5.2.1. Randomisation 
5.2.2. Inclusion 
5.2.3. Duration of treatment and Follow up 
6. STUDY MEDICATION 
6.1. DOCETAXEL IN COMBINATION WITH CISPLATIN (ARM A) 
6.2. DOCETAXEL IN COMBINATION WITH CISPLATIN AND 5 FLUOROURACIL (ARM B) 
6.3. CISPLATIN IN COMBINATION WITH 5 FLUOROURACIL (ARM C) 
6.4. PROPHYLACTIC MEDICATION REGIMEN 
6.4.3. Prophylactic use of Recombinant Granulocyte Colony Stimulating Factor (G CSF) 
6.4.4. Ethyol 
6.5. CONCOMITANT TREATMENTS 
6.6. DOSE MODIFICATION AND DOSE DELAY 
6.6.1. Dose adjustments in all arms for phase Ill 
6.6.2. Docetaxel dose adjustments 
6.6.3. Cisplatin dose adjustments 
6.6.4. 5 FU Dose Adjustments 
6.6.5. Other toxic effects 
6.7. CISPLATIN (NO DOSE MODIFICATION REQUIRED) 
6.8. METHODS FOR ASSIGNING PATIENTS TO TREATMENT GROUPS 
6.9. PACKAGING AND LABELLING 
6.9.2. Cisplatin 
6.9.3. 5 fluorouracil 
6.10. DRUG ACCOUNTABILITY 
7. STUDY ASSESSMENTS 
7.1.1.2. Unidimensionally measurable lesions 
7.1.2.2. Response criteria 
7.1.3. WHO criteria for measurement of response 
7.1.3.2. Evaluable not measurable disease 
7.1.3.3. Not evaluable lesions 
7.1.4.3. Determination of the overall response in case of presence of only evaluable not measurable 
7.1.5. Determination of best overall response 
7.1.7. Evaluation of clinical benefit 
7.2. SAFETY ASSESSMENT METHODS 
7.2.2. Laboratory determinations 
7.3. QUALITY OF LIFE EVALUATION 
8. ADVERSE EVENTS 
8.1. DEFINITIONS 
8.2. RECORDING OF ADVERSE EVENTS 
8.3. REPORTING OF SERIOUS ADVERSE EVENTS 
8.4. PATIENT REMOVAL FROM STUDY THERAPY DUE TO ADVERSE EVENTS 
8.5. DEATH 
9. DATAANALYSIS 
9.1. SAMPLE SIZE 
9.2. STATISTICAL ANALYSIS 
9.2.1. Definition of populations 
9.2.2. Statistical methods 
9.2.4. Phase Ill Interim Analysis 
9.2.5. Clinical benefit evaluation 
9.3. QUALITY OF LIFE 
10. INVESTIGATOR I SPONSOR OBLIGATIONS 
10.1. ETHICS 
10.3. PATIENT INFORMED CONSENT 
10.4. MODIFICATION OF THE PROTOCOL 
10.5. INSURANCE AND LIABILITY 
10.6. RECORDS RETENTION/PATIENT IDENTIFICATION 
10.7. USE OF INFORMATION AND PUBLICATION 
11. APPENDICES 